Importantly, the current evidence supporting this approach is largely indirect and derived from studies conducted in patients with established PsO and metabolic comorbidities, rather than in well-characterized early PsA cohorts.An additional and largely underexplored aspect concerns the safety of combining GLP-1RAs with bDMARDs
Losing weight can be difficult when appetite, metabolic health, medications, medical conditions, stress and daily routines work against your efforts
Note: Compounded medications are customized for individual needs and are not reviewed or approved by the FDA for safety or effectiveness
Current Regulatory Status Retatrutide has not received approval from Health Canada or any other regulatory body worldwide
In animal models, GLP-1 receptor agonists reduce cocaine, methamphetamine/amphetamine, and nicotine-related behaviors, including drug taking, motivation to use, and relapse-like seeking